glp-1 gip lilly First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, & Glucagon triple hormone receptor agonist drug leads to nearly 29% weight loss in first pivotal test! Eli announced positive topline results from the Media Centre | EASD

Mounjaro News & Lawsuit Updates Prior to 2025 December 2, 2024: Number of Mounjaro and GLP-1 Lawsuits Grows to 1,300 in December As of December 2, 2024, 1,300 people have alleged injuries from Mounjaro and other GLP-1 drugs and filed lawsuits as part of multidistrict litigation

Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators

Early evidence and clinical experience suggest real potential for people with chronic pain, especially neuropathy, fibromyalgia, and degenerative joint conditions

www.numerator.com

The recommended foods for GLP-1 users provide an excellent framework for meal planning during the starting dose period and beyond

Antioxidant 9(8):681